study

Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab

TOKYO, Mar 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (BAN2401). The lecanemab... » read more

IMH to conduct second study on dementia and depression among elderly

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

HONG KONG, Feb 7, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 21... » read more

Eisai’s Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study

TOKYO, Jan 19, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has enrolled the first subject in the phase II/III study (Tau NexGen study). The study will assess the effect of Eisai’s... » read more

Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium

TOKYO, Jan 17, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, “lenvatinib”) will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22),... » read more

Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation

TOKYO, Dec 24, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early Alzheimer’s disease (AD), was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). FDA granted Breakthrough Therapy designation for lecanemab... » read more

Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference

TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across multiple statistical models in patients with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early... » read more

Eisai: Introduction of Plasma-based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced a presentation about exploring the use of plasma-based biomarkers in the Phase 3 AHEAD 3-45 study of lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody. AHEAD 3-45 is the first preclinical Alzheimer’s disease (AD)... » read more

Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer’s Disease

TOKYO, Nov 9, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has an agreement with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to amend the clinical... » read more

Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin

SHANGHAI, Sep 26, 2021 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (“Hua Medicine”; SEHK: 2552) today announced that at the 6th China BioMed Innovation and Investment Conference held September 25-27 in Suzhou, China (the “CBIIC”), Professor Jianhua MA, Director of the Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society,... » read more

SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases

HONG KONG, Sep 17, 2021 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (HKEX 3681.HK, “SinoMab”) announced with Suzhou Sinovent Pharmaceuticals Co., Ltd. (“Sinovent”) today that they have entered into an exclusive licensing agreement with Everest Medicines (HKEX 1952.HK, “Everest”) to out-license the right to develop and commercialize SN1011 (referred as “XNW1011” by Sinovent),... » read more

Toyota: Feasibility Study on the Receiving and Distribution Business of Imported Hydrogen in Chubu Regio

Toyota City, Japan, Aug 6, 2021 – (JCN Newswire via SEAPRWire.com) – Sumitomo Corporation, Chiyoda Corporation, Toyota Motor Corporation, Japan Research Institute, Limited, and Sumitomo Mitsui Banking Corporation (collectively, “Joint Contractors”) have been appointed by the New Energy and Industrial Technology Development Organization (“NEDO”) to conduct a feasibility study on the receiving and distribution business... » read more

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)

TOKYO, Jul 30, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab (development code: BAN2401) — granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in June 2021 — following 18 months of treatment... » read more

Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021

TOKYO, Jul 30, 2021 – (JCN Newswire via SEAPRWire.com) – Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo) today announced that Biogen led a late-breaking presentation on the design of the first real-world observational Phase 4 study in Alzheimer’s disease called ICARE AD-US, at the Alzheimer’s Association International Conference (AAIC), being held both virtually and... » read more

Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer’s Disease and Dementia at AAIC 2021

TOKYO, Jul 21, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the company will conduct a total of 11 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401) for which the U.S. Food and Drug Administration has granted Breakthrough Therapy designation, at... » read more

Mitsubishi Motors (Thailand) Signs MoU with Eternity Grand Logistics to Do a Pilot Study on Commercial Usage of Compact EVs

TOKYO, Jul 16, 2021 – (JCN Newswire via SEAPRWire.com) – Mitsubishi Motors Corporation (MMC) announced that Mitsubishi Motors Thailand Co., Ltd. (MMTh), MMC’s subsidiary in Thailand, has signed a Memorandum of Understanding (MoU) on June 9 with Eternity Grand Logistics Public Co., Ltd. (Eternity), a logistics company of the Hitachi Transport System Group, to conduct... » read more

Children in Singapore as young as 3 show racial preference

SINGAPORE – Pre-school children here can develop racial preferences by the age of three, especially if they belong to the majority race, a study by Nanyang Technological University has found. The study showed that Chinese children in pre-schools, unlike their Indian peers, showed implicit bias (unconscious attitudes) and explicit bias (overt biased behaviours) favouring their... » read more

Football: Fifa to carry out study on holding World Cup every two years

MANCHESTER, ENGLAND (REUTERS) – Fifa will carry out a feasibility study on holding the World Cup and the women’s World Cup every two years after backing a proposal at its annual congress on Friday (May 21). The two competitions are currently held every four years but the Saudi Arabian Football Federation (SAFF) put forward a... » read more

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications

TOKYO, May 7, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd.and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for applications seeking two new approvals for the combination of... » read more

Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting

TOKYO, Apr 14, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401), its dual orexin receptor antagonist lemborexant (product name: Dayvigo) and its antiepileptic drug perampanel (product name: Fycompa), at... » read more